After merging with Acceleron Pharma for $11.5 billion last year, Merck & Co (MRK.N) has announced its therapy has met the main goal of a late-stage study in patients with progressive blood vessel disorders, Reuters reports.
When compared with placebo, Statercept significantly extended the distance patients with pulmonary arterial hypertension (PAH) could walk in six minutes.
When compared with placebo, statercept significantly extended the distance patients with pulmonary arterial hypertension (PAH) could walk in six minutes.
Merck estimates that its cardiovascular portfolio could generate $10 billion in peak sales by 2030, consisting of eight approved drugs.
Merck estimates that 40,000 Americans suffer from pulmonary arterial hypertension, a rare form of high blood pressure.
